Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes

Antonio Lo Casto, Vincenzo Serretta, Gianluca Mortellaro, Marina Gueci, Giuseppe Ferrera, Francesco Cuccia, Vito Valenti, Nicoletta Luca, Antonella Tripoli, Antonella Elena Tripoli, Gianluca Mortellaro, Marina Gueci, Nicoletta Luca, Vito Valenti

Risultato della ricerca: Article

2 Citazioni (Scopus)

Abstract

Purpose: This is a mono-institutional study of acute and late toxicities and early biochemical control of a retrospective series of 75 prostate cancer patients treated with moderate postoperative hypofractionation delivered by helical tomotherapy (HT).Patients and methods: From April 2013 to June 2017, 75 patients received adjuvant (n=37) or salvage (n=38) treatment, delivering to prostate bed a total dose of 63.8 Gy (equivalent dose in 2-Gy fraction..67.4 Gy) using 2.2 Gy fractions. Whole-pelvis irradiation was performed in 63% of cases (median dose, 49.3 Gy; range, 48-55.1 Gy). Concurrent hormonal therapy was administered in 46% of cases. Common Terminology Criteria for Adverse Events (version 4.0) was adopted for acute and late genitourinary (GU) and gastrointestinal (GI) toxicity evaluations. Biochemical progression was defined as PSA level increase of >= 0.2 or more above the postoperative radiotherapy (RT) nadir.Results: Acute GU toxicities were as follows: G1 in 46% and G2 in 4%, detecting no G >= 3 events. For GI toxicity, we recorded G1 in 36% and G2 in 18%. With a median follow-up of 30 months (range, 12-58 months), we found late toxicity G2 GI in 6.6% and G >= 2 GU in 5.3%, including two patients who underwent surgical incontinence correction. Acute toxicity and diabetes were found to be predictive of late GI >= 2 toxicity (P=0.04 and P=0.0019). Actuarial 2- and 3-year biochemical recurrence-free survivals were 88% and 73%, respectively, for the entire population.Conclusion: In our experience, moderate hypofractionated postoperative RT with HT was feasible and safe, with reports of low incidence of toxicity and promising biochemical control rates.
Lingua originaleEnglish
pagine (da-a)5053-5060
Numero di pagine8
RivistaCancer Management and Research
Volume10
Stato di pubblicazionePublished - 2018

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology

Cita questo

Lo Casto, A., Serretta, V., Mortellaro, G., Gueci, M., Ferrera, G., Cuccia, F., Valenti, V., Luca, N., Tripoli, A., Tripoli, A. E., Mortellaro, G., Gueci, M., Luca, N., & Valenti, V. (2018). Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes. Cancer Management and Research, 10, 5053-5060.